Abstract
Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered to be a benign precursor condition that may progress to a lymphoproliferative disease or multiple myeloma. Most patients do not progress to an overt condition, but nevertheless, MGUS is associated with a shortened life expectancy and, in a minority of cases, a number of co-morbid conditions that include an increased fracture risk, renal impairment, peripheral neuropathy, secondary immunodeficiency, and cardiovascular disease. This review aims to consolidate current evidence for the significance of these co-morbidities before considering how best to approach these symptoms and signs, which are often encountered in primary care or within a number of specialties in secondary care.
Original language | English |
---|---|
Article number | 1554 |
Pages (from-to) | 1-16 |
Number of pages | 16 |
Journal | Cancers |
Volume | 12 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2020 |
Keywords
- Fracture
- MGRS
- MGUS
- Multiple myeloma
- Neuropathy
- Osteoporosis
- Paraprotein